Twist confers chemoresistance to anthracyclines in bladder cancer through upregulating P-glycoprotein

Chemotherapy

Volumn 58, Issue 4, 2012, Pages 264-272

  Chen, Yule ^a   Li, Lei ^a,b   Zeng, Jin ^a   Wu, Kaijie ^a   Zhou, Jiancheng ^a   Guo, Peng ^b   Zhang, Dong ^a   Xue, Yan ^a   Liang, Liang ^a   Wang, Xinyang ^a,b   Chang, Luke S ^a   He, Dalin ^a,b  

^a THE FIRST AFFILIATED HOSPITAL OF XI AN JIAOTONG UNIVERSITY   (China)

^b BEIJING UNIVERSITY OF POSTS AND TELECOMMUNICATIONS   (China)

Author keywords

Anthracyclines; Bladder cancer; Chemo resistance; P glycoprotein; Twist

Indexed keywords

DOXORUBICIN; MESSENGER RNA; MULTIDRUG RESISTANCE PROTEIN 1; PIRARUBICIN; SMALL INTERFERING RNA; TRANSCRIPTION FACTOR TWIST; VERAPAMIL;

ADULT; AGED; ARTICLE; BLADDER CANCER; CANCER CELL CULTURE; CANCER RESISTANCE; CANCER TISSUE; CELL NUCLEUS; CELL VIABILITY; CHEMOSENSITIZATION; DRUG EXPOSURE; FEMALE; GENE EXPRESSION REGULATION; HUMAN; HUMAN CELL; HUMAN TISSUE; IC 50; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; UPREGULATION;

ADULT; AGED; AGED, 80 AND OVER; ANTHRACYCLINES; ANTIBIOTICS, ANTINEOPLASTIC; CELL LINE, TUMOR; DOXORUBICIN; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; MALE; MIDDLE AGED; P-GLYCOPROTEIN; RNA INTERFERENCE; RNA, SMALL INTERFERING; TWIST TRANSCRIPTION FACTOR; UP-REGULATION; URINARY BLADDER NEOPLASMS;

EID: 84866177029     PISSN: 00093157     EISSN: 14219794     Source Type: Journal    
DOI: 10.1159/000341860     Document Type: Article

References (42)

1. de Martel C, Ferlay J, Franceschi S, Vignat J, Bray F, Forman D, Plummer M: Global burden of cancers attributable to infections in 2008: a review and synthetic analysis. Lancet Oncol 2012; 13: 607-615.
2. Skinner EC: Challenges in the modern treatment of muscle-invasive bladder cancer. Oncology (Williston Park) 2011; 25: 1405-1406.
3. Chang A: Chemotherapy, chemoresistance and the changing treatment landscape for NSCLC. Lung Cancer 2011; 71: 3-10.
4. Coley HM: Mechanisms and strategies to overcome chemotherapy resistance in metastatic breast cancer. Cancer Treat Rev 2008; 34: 378-390.
5. Morrison R, Schleicher SM, Sun Y, Niermann KJ, Kim S, Spratt DE, Chung CH, Lu B: Targeting the mechanisms of resistance to chemotherapy and radiotherapy with the cancer stem cell hypothesis. J Oncol 2011; 2011: 941876.
6. Baumeister P, Reiter M, Schwenk-Zieger S, Harreus U: Transforming growth factor alpha stimulation of mucosal tissue cultures from head and neck squamous cell carcinoma patients increases chemoresistance to cisplatin. Chemotherapy 2010; 56: 268-274.
7. Karlsson JE, Heddle C, Rozkov A, Rotticci-Mulder J, Tuvesson O, Hilgendorf C, Andersson TB: High-activity P-glycoprotein, multidrug resistance protein 2, and breast cancer resistance protein membrane vesicles prepared from transiently transfected human embryonic kidney 293-epstein-barr virus nuclear antigen cells. Drug Metab Dispos 2010; 38: 705-714.
8. Tada Y, Wada M, Migita T, Nagayama J, Hinoshita E, Mochida Y, Maehara Y, Tsuneyoshi M, Kuwano M, Naito S: Increased expression of multidrug resistance-associated proteins in bladder cancer during clinical course and drug resistance to doxorubicin. Int J Cancer 2002; 98: 630-635.
9. Clifford SC, Thomas DJ, Neal DE, Lunec J: Increased mdr1 gene transcript levels in high-grade carcinoma of the bladder determined by quantitative PCR-based assay. Br J Cancer 1994; 69: 680-686.
10. Hasegawa S, Abe T, Naito S, Kotoh S, Kumazawa J, Hipfner DR, Deeley RG, Cole SP, Kuwano M: Expression of multidrug resistance-associated protein (MRP), MDR1 and DNA topoisomerase II in human multidrug-resistant bladder cancer cell lines. Br J Cancer 1995; 71: 907-913.
11. Kausch I, Bohle A: Molecular aspects of bladder cancer III: prognostic markers of bladder cancer. Eur Urol 2002; 41: 15-29.
12. Hoffmann AC, Wild P, Leicht C, Bertz S, Danenberg KD, Danenberg PV, Stohr R, Stockle M, Lehmann J, Schuler M, Hartmann A: MDR1 and ERCC1 expression predict outcome of patients with locally advanced bladder cancer receiving adjuvant chemotherapy. Neoplasia 2010; 12: 628-636.
13. Barnes RM, Firulli AB: A twist of insight-the role of twist-family bHLH factors in development. Int J Dev Biol 2009; 53: 909-924.
14. Cakouros D, Raices RM, Gronthos S, Glackin CA: Twist-ing cell fate: mechanistic insights into the role of twist in lineage specification/ differentiation and tumorigenesis. J Cell Biochem 2010; 110: 1288-1298.
15. Karreth F, Tuveson DA: Twist induces an epithelial-mesenchymal transition to facilitate tumor metastasis. Cancer Biol Ther 2004; 3: 1058-1059.
16. Ansieau S, Puisieux A: An alternate model of tumoral progression (in French). Biol Aujourdhui 2011; 205: 47-52.
17. Tjensvoll K, Oltedal S, Farmen RK, Shammas FV, Heikkila R, Kvaloy JT, Gilje B, Smaaland R, Nordgard O: Disseminated tumor cells in bone marrow assessed by TWIST1, cytokeratin 19, and mammaglobin A mRNA predict clinical outcome in operable breast cancer patients. Clin Breast Cancer 2010; 10: 378-384.
18. Zhang Z, Xie D, Li X, Wong YC, Xin D, Guan XY, Chua CW, Leung SC, Na Y, Wang X: Significance of TWIST expression and its association with E-cadherin in bladder cancer. Hum Pathol 2007; 38: 598-606.
19. Fondrevelle ME, Kantelip B, Reiter RE, Chopin DK, Thiery JP, Monnien F, Bittard H, Wallerand H: The expression of twist has an impact on survival in human bladder cancer and is influenced by the smoking status. Urol Oncol 2009; 27: 268-276.
20. Shiota M, Yokomizo A, Itsumi M, Uchiumi T, Tada Y, Song Y, Kashiwagi E, Masubuchi D, Naito S: Twist1 and Y-box-binding protein-1 promote malignant potential in bladder cancer cells. BJU Int 2011; 108:E142-E149.
21. Zeng J, Sun Y, Wu K, Li L, Zhang G, Yang Z, Wang Z, Zhang D, Xue Y, Chen Y, Zhu G, Wang X, He D: Chemopreventive and chemotherapeutic effects of intravesical silibinin against bladder cancer by acting on mitochondria. Mol Cancer Ther 2011; 10: 104-116.
22. Yin T, Wei H, Leng Z, Yang Z, Gou S, Wu H, Zhao G, Hu X, Wang C: Bmi-1 promotes the chemoresistance, invasion and tumorigenesis of pancreatic cancer cells. Chemotherapy 2011; 57: 488-496.
23. Poljakova J, Eckschlager T, Hrebackova J, Hrabeta J, Stiborova M: The comparison of cytotoxicity of the anticancer drugs doxorubicin and ellipticine to human neuroblastoma cells. Interdiscip Toxicol 2008; 1: 186-189.
24. Sliwinska MA, Mosieniak G, Wolanin K, Babik A, Piwocka K, Magalska A, Szczepanowska J, Fronk J, Sikora E: Induction of senescence with doxorubicin leads to increased genomic instability of HCT116 cells. Mech Ageing Dev 2009; 130: 24-32.
25. Alexander NR, Tran NL, Rekapally H, Summers CE, Glackin C, Heimark RL: N-cadherin gene expression in prostate carcinoma is modulated by integrin-dependent nuclear translocation of Twist1. Cancer Res 2006; 66: 3365-3369.
26. Yusa K, Tsuruo T: Reversal mechanism of multidrug resistance by verapamil: direct binding of verapamil to P-glycoprotein on specific sites and transport of verapamil outward across the plasma membrane of K562/ADM cells. Cancer Res 1989; 49: 5002-5006.
27. Abolhoda A, Wilson AE, Ross H, Danenberg PV, Burt M, Scotto KW: Rapid activation of MDR1 gene expression in human metastatic sarcoma after in vivo exposure to doxorubicin. Clin Cancer Res 1999; 5: 3352-3356.
28. Campone M, Vavasseur F, Le Cabellec MT, Meflah K, Vallette FM, Oliver L: Induction of chemoresistance in HL-60 cells concomitantly causes a resistance to apoptosis and the synthesis of P-glycoprotein. Leukemia 2001; 15: 1377-1387.
29. Nakagawa M, Emoto A, Nasu N, Hanada T, Kuwano M, Cole SP, Nomura Y: Clinical significance of multi-drug resistance associated protein and P-glycoprotein in patients with bladder cancer. J Urol 1997; 157: 1260-1265.
30. Kim WJ, Kim EJ, Kim SK, Kim YJ, Ha YS, Jeong P, Kim MJ, Yun SJ, Lee KM, Moon SK, Lee SC, Cha EJ, Bae SC: Predictive value of progression-related gene classifier in primary non-muscle invasive bladder cancer. Mol Cancer 2010; 9: 3.
31. Lee JS, Leem SH, Lee SY, Kim SC, Park ES, Kim SB, Kim SK, Kim YJ, Kim WJ, Chu IS: Expression signature of E2F1 and its associated genes predict superficial to invasive progression of bladder tumors. J Clin Oncol 2010; 28: 2660-2667.
32. Thisse B, Stoetzel C, Gorostiza-Thisse C, Perrin-Schmitt F: Sequence of the twist gene and nuclear localization of its protein in endomesodermal cells of early Drosophila embryos. Embo J 1988; 7: 2175-2183.
33. Cheng GZ, Chan J, Wang Q, Zhang W, Sun CD, Wang LH: Twist transcriptionally upregulates AKT2 in breast cancer cells leading to increased migration, invasion, and resistance to paclitaxel. Cancer Res 2007; 67: 1979-1987.
34. Zhuo WL, Wang Y, Zhuo XL, Zhang YS, Chen ZT: Short interfering RNA directed against TWIST, a novel zinc finger transcription factor, increases A549 cell sensitivity to cisplatin via MAPK/mitochondrial pathway. Biochem Biophys Res Commun 2008; 369: 1098-1102.
35. Kwok WK, Ling MT, Lee TW, Lau TC, Zhou C, Zhang X, Chua CW, Chan KW, Chan FL, Glackin C, Wong YC, Wang X: Up-regulation of TWIST in prostate cancer and its implication as a therapeutic target. Cancer Res 2005; 65: 5153-5162.
36. Wang X, Ling MT, Guan XY, Tsao SW, Cheung HW, Lee DT, Wong YC: Identification of a novel function of TWIST, a bHLH protein, in the development of acquired taxol resistance in human cancer cells. Oncogene 2004; 23: 474-482.
37. Li QQ, Xu JD, Wang WJ, Cao XX, Chen Q, Tang F, Chen ZQ, Liu XP, Xu ZD: Twist1-mediated adriamycin-induced epithelialmesenchymal transition relates to multidrug resistance and invasive potential in breast cancer cells. Clin Cancer Res 2009; 15: 2657-2665.
38. Sheu MT, Liou YB, Kao YH, Lin YK, Ho HO: A quantitative structure-activity relationship for the modulation effects of flavonoids on P-glycoprotein-mediated transport. Chem Pharm Bull (Tokyo) 2010; 58: 1187-1194.
39. Chaudhary PM, Roninson IB: Induction of multidrug resistance in human cells by transient exposure to different chemotherapeutic drugs. J Natl Cancer Inst 1993; 85: 632-639.
40. Li F, Sethi G: Targeting transcription factor NF-B to overcome chemoresistance and radioresistance in cancer therapy. Biochim Biophys Acta 2010; 1805: 167-180.
41. Pham CG, Bubici C, Zazzeroni F, Knabb JR, Papa S, Kuntzen C, Franzoso G: Upregulation of Twist-1 by NF-B blocks cytotoxicity induced by chemotherapeutic drugs. Mol Cell Biol 2007; 27: 3920-3935.
42. Weinstein RS, Jakate SM, Dominguez JM, Lebovitz MD, Koukoulis GK, Kuszak JR, Klusens LF, Grogan TM, Saclarides TJ, Roninson IB, et al: Relationship of the expression of the multidrug resistance gene product (P-glycoprotein) in human colon carcinoma to local tumor aggressiveness and lymph node metastasis. Cancer Res 1991; 51: 2720-2726.